Navigation Links
Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
Date:5/15/2008

Randomized TRIAS HR Pilot Study Compares Genous, Boston Scientific's

Taxus(R) Other Presentations Focus on Real-World Use of Genous, Stent's Performance

in Patients with AMI, Those Who Could Not Tolerate Dual-Antiplatelet

Therapy

BARCELONA, Spain, May 15 /PRNewswire/ -- OrbusNeich today announced that multiple clinical data presentations in a symposium at EuroPCR 2008 support the use of the company's Genous Bio-engineered R stent, the world's first pro-healing stent, as a safe alternative to drug-eluting stents.

12-Month TRIAS HR Pilot Study Data

Presented by Robbert de Winter, M.D., Ph.D., of the Academic Medical Center in Amsterdam, data from the TRIAS HR (high risk) Pilot study show similar target vessel failure (TVF) rates at 12-month follow-up for OrbusNeich's Genous Bio-engineered R stent and Boston Scientific's Taxus stent in high risk of restenosis patients.

In the patients treated with Taxus, there were four out-of-hospital thrombotic events, while there were no reported events in the Genous group. TRIAS HR Pilot is a randomized, 193-patient, single-center, prospective, single-blind study involving patients with a high risk of restenosis. High risk of restenosis is defined as patients who have diabetes mellitus and/or small vessels (less than 2.8 mm) and/or long lesions (greater than 23 mm) and/or chronic total occlusions.

"Interventional cardiologists need better stent technologies," said de Winter, principal investigator of the TRIAS HR Pilot study. "A pro-healing approach with the Genous stent is a viable one. We look forward to obtaining further data on the stent's performance in our large, multi-center TRIAS trials that compare Genous to both drug-eluting and bare metal stents."

e-HEALING Interim Patient Subset Data

In addition, de Winter presented interim follow-up data from patient subsets of e-HEALING, a monitored, m
'/>"/>

SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Ill. , July 31, 2015 ... ® (NABP ® ) issued a report ... ensuring that action is taken against websites illegally ... Internet Drug Outlet Identification Program Progress Report ... , thousands of websites illegally distribute ...
(Date:7/31/2015)... CHICAGO , July 31, 2015 ... Market by Product (Moist Heat, Dry Heat, Ethylene Oxide, Filtration, ... & End User (Hospitals, Pharmaceuticals) - Global Forecast to 2020", ... reach around USD 6.1 Billion by 2020, at a CAGR ... 242 market data T ables and ...
(Date:7/31/2015)... 31, 2015  Semler Scientific, Inc. (Nasdaq: SMLR ... to healthcare insurers and physician groups, today reported financial ... "In the second quarter of 2015, ... growth of 54%, quarter over quarter revenue growth of ... base of FloChec® units of 18%," said Doug Murphy-Chutorian, ...
Breaking Medicine Technology:NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
... March 20 Santaris Pharma announced today that,the ... clinic. In the USA,several patients with cancer have ... is jointly developed by Santaris Pharma and Enzon,Pharmaceuticals. ... Enzon Pharma­ceutical,s Investigational New Drug (IND) application,for the ...
... REHOVOT, Israel, March 18 XTL Biopharmaceuticals,Ltd. (Nasdaq: ... has entered into an,asset purchase agreement with Bio-GAL Ltd, ... on Recombinant Erythropoietin ("rHuEPO") for the prolongation,of multiple myeloma ... , MM is a severe ...
Cached Medicine Technology:Another LNA-based RNA Inhibitor Enters Clinical Trials 2Another LNA-based RNA Inhibitor Enters Clinical Trials 3XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma 2XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma 3
(Date:8/1/2015)... ... ... and Lita Hart, icons of the network marketing industry and founders of the Healthy ... Movement of EvolvHealth. In what has been a long-term relationship between the companies for ... of purpose together to change the course of the network marketing industry. , “This ...
(Date:8/1/2015)... ... ... Lume Wellness creators Alex, Robert, and Sam have announced update 3.0.1 to this ... The app is designed to track various metrics of wellness, including physical activity, diet, ... and use this information for positive behavior modification. Lume Wellness keeps track of both ...
(Date:8/1/2015)... Hartford, CT (PRWEB) , ... August 01, 2015 , ... On March 19, 2015 Phil ... 2,175 mile trek of the Appalachian Trail by stepping off Springer Mountain and ... , On July 26th Phil reached Connecticut and was greeted by friends and family. ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned ... debuted their new type of sod called Leisure Time(TM) zoysia . It's nicknamed ... , To commemorate introduction of this new type of sod, Super-Sod is giving away ...
(Date:7/31/2015)... ... 31, 2015 , ... Ticket Down is a reliable source for authentic tickets ... Grant Park. The festival will end on Sunday, August 2nd. , ... annual Lollapalooza. This unique and unbelievably popular festival attracts the best in entertainment ...
Breaking Medicine News(10 mins):Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2
... procedure cuts conception rate, study found , THURSDAY, Oct. ... 15 minutes after being artificially inseminated greatly boost their ... women treated for subfertility with IUI [intrauterine insemination] to ... higher chance at conceiving," said Inge Custers, lead author ...
... In ... announced the launch of its online floral gift program, celebrating caregivers who love and ... with aging. , ... Camarillo, California (PRWEB) October 30, 2009 -- In recognition of November,s Alzheimer,s Awareness Month, ...
... thrown off schedule by Daylight Saving Time , FRIDAY, ... you,ll get in most parts of the country over the ... Time could spell trouble for your body clock, a sleep ... the sleep disorders research program in the division of sleep ...
... led to bigger, healthier infants, studies show , FRIDAY, ... the list of people who should get H1N1 swine ... highlight the benefits of vaccination for moms-to-be and their ... reduced rates of hospitalization top the findings, which are ...
... AMERIGROUP Corporation (NYSE: AGP ) today announced that net ... $0.43 per diluted share, versus $37.9 million, or $0.71 per diluted ... are in line with the preliminary earnings range that the Company ... elevated medical costs associated with the onset of what appears to ...
... AcelRx Pharmaceuticals, Inc. today announced that it ... the FDA for ARX-01, a drug/device combination product ... which enables delivery of sufentanil by the non-invasive ... alternative to intravenous patient-controlled analgesia (IV PCA) for ...
Cached Medicine News:Health News:Lying Still Raises Artificial Insemination Success 2Health News:Lying Still Raises Artificial Insemination Success 3Health News:Forget-Me-Not-Flower-Club Launches Floral Gift Program For Caregivers: Alzheimer's Awareness Month Program Offers Resources, Recognition for Friends and Family 2Health News:Forget-Me-Not-Flower-Club Launches Floral Gift Program For Caregivers: Alzheimer's Awareness Month Program Offers Resources, Recognition for Friends and Family 3Health News:When Clocks Change, Body May Need Time to Adjust 2Health News:Flu Shot in Pregnancy Protects Baby 2Health News:Flu Shot in Pregnancy Protects Baby 3Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 2Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 3Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 4Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 5Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 6Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 7Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 8Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 9Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 10Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 11Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 12Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 13Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 14Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 15Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 16Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 17Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 18Health News:AcelRx Announces Successful Completion of End-of-Phase 2 Meeting on ARX-01, Sufentanil NanoTab PCA System for Post-Operative Pain Management 2Health News:AcelRx Announces Successful Completion of End-of-Phase 2 Meeting on ARX-01, Sufentanil NanoTab PCA System for Post-Operative Pain Management 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: